Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants.

Grau, Santiago; Solano, Carlos; García-Vidal, Carol; Jarque, Isidro; Barrueta, Jon A; Peral, Carmen; Rodríguez, Irene; Rubio-Rodríguez, Darío; Rubio-Terrés, Carlos

Grau, Santiago; Solano, Carlos; García-Vidal, Carol; Jarque, Isidro; Barrueta, Jon A; Peral, Carmen; Rodríguez, Irene; Rubio-Rodríguez, Darío; Rubio-Terrés, Carlos.

Afiliação

Grau S; Hospital del Mar (IMIM), Barcelona, Spain.
Solano C; Hospital Clínico Universitario, Valencia, Spain.
García-Vidal C; Hospital Universitari de Bellvitge, Barcelona, Spain.
Jarque I; Hospital Universitario La Fe, Valencia, Spain.
Barrueta JA; Pfizer S.L.U., Alcobendas (Madrid), Spain.
Peral C; Pfizer S.L.U., Alcobendas (Madrid), Spain.
Rodríguez I; Trial Form Support, Madrid, Spain.
Rubio-Rodríguez D; Health Value, Madrid, Spain.
Rubio-Terrés C; Health Value, Madrid, Spain.

J Health Econ Outcomes Res ; 3(2): 153-161, 2016.

Article em En | MEDLINE | ID: mdl-35619591

Palavras-chave

allogeneic hematopoietic stem cell transplant; cost-effectiveness analysis; invasive fungal infections; micafungin; posaconazole; prophylaxis; voriconazole

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Health_economic_evaluation / Prognostic_studies Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google